1 / 18

WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence Quality of BE Studies

WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence Quality of BE Studies Kiev, October 3-7, 2005 Dr. H. Potthast (h.potthast@bfarm.de). Regulations. ICH-GCP guideline (CPMP/ICH/135/95) Guide to GMP incl. Annex 13 WHO documents

kalista
Download Presentation

WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence Quality of BE Studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence Quality of BE Studies Kiev, October 3-7, 2005 Dr. H. Potthast (h.potthast@bfarm.de)

  2. Regulations • ICH-GCP guideline (CPMP/ICH/135/95) • Guide to GMP incl. Annex 13 • WHO documents • EU “Note for Guidance on the Investigation of Bioavailability and Bioequivalence” CPMP/EWP/QWP/1401/98, related guidances and others

  3. Legal Basis • acc. to e.g. Directive 2001/20/EC: “The verification of compliance with the standards of good clinical practice and the need to subject data, information and documents to inspection in order to confirm that they have been properly generated, recorded and reported are essential in order to justify the involvement of human subjects in clinical trials.”  finding/definition of inspection triggers

  4. Assessment Process • General Requirements  BE studies as a substitute for clinical and preclinical data  Quality of the BE study is of decisive importance for approval of the product

  5. Inspection Triggers • Environmental triggers - examples  random selection acc. to annual inspection program  information from other regulatory authorities • type of product (e.g. particular narrow therap. range) • lack of previous inspections for product/applicant/location • …… • general indication for inspection

  6. Inspection Triggers • Early phase triggers - examples  history of (serious) problems for sponsor, CRO, sites, labs • involvement of clinical site/CRO/labs in many studies • business related issues (e.g. bankruptcy, mergers) • lack of audit certificates • ….. • Still general indication without direct implication of trial data

  7. Inspection Triggers • Evaluation phase triggers - examples  protocol gives incomplete/illogical information • numerous protocol violations • unsatisfactory explanation for protocol violations • data too clean/too messy • number of missing values/drop outs/nds…. • Findings due to knowledge from literature and other studies; type of generic product already known

  8. Inspection Triggers • Evaluation phase triggers – contd.  conflicting (PK-)results as compared to known data • insufficient documentation (clinic, analytics, statistics) • missing documentation • implausibility/inconsistency of clinical or analytical data (e.g. long half-life – short wash-out – no carry-over?!) • doubtful statistics or change in the analysis….

  9. Inspection Triggers • Information exchange • evaluation of triggers positive (negative – non serious/’formal’) negative – serious  request/list of questions  EMEA inspection data base since 2004

  10. Inspections • Evaluation/Inspection based on source data/raw data e.g. • print outs of chromatograms  signed CRFs  analytic protocols • time schedules • list of providers …….

  11. Inspections Data verification & QA issues • GCP compliance statement available? • audit/monitoring reports available? • protocol valid, i.e. signed (incl. amendments)? • was the protocol followed? • genuine study subjects/volunteers? • archiving of source/raw data? • violations of the protocol justified?

  12. Inspections Data verification & QA issues ctd. • excluded subjects - traceable? • consistent trial results? • final responsibility of investigators (signing)? • source of investigative products? • batch information available? • handling of investigative products?

  13. Inspections Data verification & QA issues ctd. • validation of bioanalytical method? • timing • validation characteristics • adherence to GLP • SOPs available…… • calibrated equipment? • computer systems???? • archiving of bioanalytical raw data

  14. Inspections Data verification & QA issues ctd. • statistical plan adhered to? • transfer of analytical data to statistics • main pharmacokinetic characteristics • method of determination • nd values considered? • statistical outcome and conclusions consistent? • archiving of statistical raw data

  15. Inspections Regulatory & ethical issues • independent ethics committee? • ethical approval based on appropriate documentation? • protocol • amendments • investigators brochure; SPC • subjects information informed consent • approval of competent authority in time? • subjects from vulnerable populations? • signing of subjects available?

  16. Inspections Regulatory & ethical issues ctd. • insurance of subjects adequate? • adequately instructed personnel? • investigators • technicians • suppliers….. • safety evaluation assured throughout the trial? • retention samples sufficient? • storage of retention samples?

  17. Inspections FINDINGS • … • …. • … • … • …

  18. Inspections A Matter of TRUST!

More Related